Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.2 USD | +2.65% | -0.32% | +37.17% |
Financials (USD)
Sales 2024 * | 334M | Sales 2025 * | 390M | Capitalization | 1.44B |
---|---|---|---|---|---|
Net income 2024 * | 67M | Net income 2025 * | 114M | EV / Sales 2024 * | 4.31 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.68 x |
P/E ratio 2024 * |
21
x | P/E ratio 2025 * |
12.4
x | Employees | 624 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.46% |
Latest transcript on ADMA Biologics, Inc.
1 day | +2.65% | ||
1 week | -0.32% | ||
Current month | -6.06% | ||
1 month | +4.38% | ||
3 months | +23.51% | ||
6 months | +86.75% | ||
Current year | +37.17% |
Managers | Title | Age | Since |
---|---|---|---|
Adam Grossman
CEO | Chief Executive Officer | 47 | 06-06-01 |
Compliance Officer | 37 | 10-12-31 | |
Skyler Bloom
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Lawrence Guiheen
BRD | Director/Board Member | 73 | 12-07-23 |
Bryant Fong
BRD | Director/Board Member | 51 | 12-04-30 |
Steven Elms
CHM | Chairman | 60 | 06-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.07% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - | |
0.01% | 9 M€ | +4.47% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 6.2 | +2.65% | 2,983,796 |
24-04-17 | 6.04 | -1.95% | 1,711,815 |
24-04-16 | 6.16 | +3.01% | 1,764,248 |
24-04-15 | 5.98 | -0.66% | 1,815,256 |
24-04-12 | 6.02 | -3.22% | 1,480,260 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.17% | 1.44B | |
-5.99% | 84.46B | |
+3.95% | 40.85B | |
-26.37% | 27.69B | |
+50.82% | 24.28B | |
-6.59% | 17.09B | |
-32.37% | 13.67B | |
-10.45% | 11.79B | |
-15.88% | 11.86B | |
-4.04% | 8.07B |
- Stock Market
- Equities
- ADMA Stock